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The present study was carried out to evaluate antidiabetic and antihyperlipidemic effects of Dillenia 
indica methanolic leaves extracts in streptozotocin induced diabetic Wistar rats by administering graded 
oral doses (250 and 500 mg/kg body weight) for 21 days. The extract showed significant antidiabetic 
activity (p<0.001). Furthermore, the decreased body weight of rats was significantly improved after extract 
treatments. Daily oral treatment with the extract for 21 days to diabetic rats, also resulted in significant 
reduction in serum cholesterol, triglycerides and serum transaminase levels but HDL-cholesterol level 
was found to be improved (p<0.001) as compared to the diabetic control group. The extract treatment 
also showed to enhance serum insulin level in diabetic rats as compared to the diabetic control group. 
In conclusion, D. indica leaf extract might be useful for diabetes mellitus management and other 
abnormalities associated with this metabolic disorder.
Uniterms: Dillenia indica/antidiabetic effects/experimental study. Dillenia indica/antihyperlipidemic 
effects/experimental study. Antidiabetics/experimental study. Serum transaminase. Serum cholesterol. 
HDL-cholesterol level.
Realizou-se o presente estudo para avaliar os efeitos antidiabético e anti-hiperlipidêmico de extratos 
metanólicos de folhas de Dillenia indica em ratos wistar com diabetes induzido por estreptozotocina 
por meio da administração de doses orais (250 e 500 mg/kg de peso corporal) por 21 dias. O extrato 
mostrou atividade antidiabética significativa (p<0,001). Além disso, a diminuição do peso corporal 
dos ratos foi significativamente melhorada após o tratamento com os extratos. O tratamento com doses 
orais do extrato por 21 dias aos ratos diabéticos também resultou em redução significativa do colesterol, 
triglicerídios e níveis de transaminase séricos, mas o nível de HDL-colesterol foi melhorado (p<0,001), 
quando comparado ao grupo controle diabético. O tratamento com extrato também mostrou aumento 
do nível sérico de insulina em ratos diabéticos comparativamente ao grupo controle diabético. Em 
conclusão, o extrato de folha de D. indica poderia ser útil para o controle do diabetes mellitus e de outras 
anormalidades associadas a essa disfunção metabólica. 
Unitermos: Dillenia indica/efeitos antidiabéticos/estudo experimental. Dillenia indica/efeito anti-
hiperlipidêmico/estudo experimental. Antidiabéticos/estudo experimental. Transaminase sérica. Colesterol 
sérico. Nível de HDL-colesterol.
INTRODUCTION
Diabetes mellitus is a metabolic disorder affecting 
carbohydrate, fat and protein metabolism that affects ne-
arly 25% of the population afflicting 150 million people, a 
figure set to rise to 300 million by 2025 (Vats et al., 2000; 
Vetrichelvan et al., 2002). The disease causes numerous 
complications such as retinopathy, neuropathy, and pe-
ripheral vascular insufficiencies (Chehade, Mooradian, 
2000). Hyperglycemia can be handled initially with oral 
synthetic agents and insulin therapy. However, these syn-
thetic agents produce some serious side effects and are 
relatively expensive for developing countries. Therefore, 
searching for effective, low cost hypoglycemic agents 
with fewer side effects is important (Rubin et al., 1994). 
Since ancient times, diabetes has been treated orally with 
several medicinal plants or their extracts based on folklore 
medicine. The World Health Organization has also recom-
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mended the evaluation of traditional plant treatments for 
diabetes (Day, 1998).
Dillenia indica Linn. (Family: Dilleniaceae) is an 
evergreen tree, 30–80 ft. in height, which bears large 
and hard fruit 3-5 in. in diameter and grows in moist and 
evergreen forests of India. The ripe fruits are widely used 
in the flavoring of curries and preparation of jam and 
jelly. The acidic juice is sweetened with sugar and used 
as a cooling drink (The Wealth of India, 1992). The fruit 
is said to possess tonic laxative properties and is used for 
relieving abdominal pain. The bark and leaves are astrin-
gent (Kirtikar, Basu, 2003). The mixed juices of leaves, 
bark and fruits are given orally for the treatment of cancer 
and diarrhea (Sharma et al., 2001). Traditionally, the plant 
is also used for treatment of diabetes (Sood et al., 2005). 
The literature survey revealed that there is no experimental 
evidence of the plant’s antidiabetic effect. Therefore, the 
present work was undertaken to explore the antidiabetic 
and antihyperlipidemic potentials of the leaves extract of 
the plant.
MATERIAL AND METHODS
Plant material
D. indica leaves were collected from the campus 
of Kurukshetra University, Kurukshetra, India during the 
month of October, 2009 and were identified by Dr. H.B. 
Singh, scientist F& Head, Raw Material Herbarium & 
Museum, NISCAIR, and New Delhi, India. A voucher 
specimen of the plant is preserved in the herbarium (NIS-
CAIR/RHMD/Consult/-2009-10/1381/182/1).
Extract preparation
The leaves were dried under shade and powdered to 
coarse particles. The powdered plant material was defatted 
with petroleum ether (60-80°C) in a Soxhlet extraction 
apparatus at 60°C and further the same amount of plant 
material extracted with methanol. The extract was dried 
at 450C in a rotary evaporator to produce a semisolid mass 
and stored in airtight containers in a refrigerator below 
10 0C.
Chemicals
Streptozotocin was purchased from Sigma-Aldrich, 
India. Total cholesterol, High density lipoprotein (HDL)-
cholesterol and triglyceride (TC), serum transaminase 
were assayed by an autoanalyser (Erba Chem 7, Man-
nheim, Germany) using standard kits from Erba diagnos-
tics Mannheim Gambh, Germany, and Blood glucose level 
was measured using an Elegance glucose meter (CT-X10) 
by Convergent Technologies, Germany. All reagents used 
in the study were analytical grade.
Animals
Wistar rats of both sexes (15 male and 15 female 
rats), weighing about 150-250 g were used in the study. 
Animals were maintained under standard environmental 
conditions i.e. ambient temperature of 22 ± 2 0C and at 
45–55% relative humidity for 12 h, each of dark and light 
cycle, and fed with a standard pellet rat diet obtained 
from Ashirwad Industries, Chandigarh, India and water 
was supplied ad libitum. All the studies were conducted 
in accordance with the Animal Ethics Committee of the 
University.
Antidiabetic studies
Induction of diabetes
After one week of acclimatization, the rats were 
subjected to a 12-h fast. Diabetes was induced with a 
single injection of streptozotocin (STZ) 60 mg/kg body 
weight i.p. The STZ was freshly dissolved in citrate buffer 
(0.01 M, pH 4.5). The blood glucose level was checked 
before and 72 h after streptozotocin injection to confirm 
the development of diabetes. The diabetic animals were 
stabilized for five days and the experiment was started on 
the next day (day 0). Only those animals which showed 
hyperglycemia (blood glucose levels >250 mg/dL) were 
used in the experiment.
Experimental design
Overnight fasted rats were divided into five groups 
and six animals were taken for each group. The extract 
was dissolved in Tween 80, 1% v/v in saline and given 
orally. Group I (Normal healthy control) received only 
vehicle (Tween 80, 1% v/v in saline). Group II served as 
the diabetic control, Group III and IV received D. indica 
methanolic leaves extract (DIME) 250 and 500 mg/kg.b.w 
respectively once a day for 21 days and Group V received 
(Glibenclamide 10 mg/kg.b.w.) once a day for 21 days and 
served as the standard.
Biochemical parameters
Blood glucose was measured with an Elegance glu-
cometer (Frankenberg, Germany) at weekly intervals i.e. 
0, 7, 14 and 21 days after daily administration of extract 
orally. On the 21st day all the animals were sacrificed 
and evaluated for the biochemical status of serum alanine 
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transaminase (ALT), aspartate transaminase (AST), and 
alkaline phosphatase (ALP) by autoanalyser using Erba 
diagnostic kits (Brandely, Maynard, 1972; Wilkinson et 
al., 1969). Serum insulin levels were determined using 
insulin ELISA kits (Kratzsch et al., 1990).
Antihyperlipidemic effect
Serum total cholesterol and triglycerides were deter-
mined by the method of Rifai et al., 1999. HDL-cholesterol 
was also evaluated in normal and streptozotocin-induced 
diabetic rats by autoanalyser using Erba diagnostic kits 
(Burstein et al., 1970).
Statistical analysis
Results are presented as mean ± standard error of 
mean (S.E.M.) The statistical analysis involving two 
groups was evaluated by means of Student’s t-test whe-
reas One way analysis of variance (ANOVA) followed 
by Dunnet’s multiple comparison post-test was used for 
statistical comparison between control and the various 
treated groups. Statistical significance was accepted at 
the p <0.05 values.
RESULTS
Effect on blood glucose level and serum insulin
Table I shows the results of blood glucose values 
in STZ-induced diabetic rats, after the daily treatment 
with the methanolic extract of D. indica (DIME 250 
and 500 mg/kg, p.o.), for 21 days. A significant decrea-
se (p<0.001) in blood glucose levels were observed in 
the groups treated with both doses of DIME of 48.64 
and 55.86%, respectively, as compared to the same 
group before treatment. At the end of the experiment 
(21st day) blood glucose level was 139.43 ± 2.28 and 
124.32 ± 1.75 mg/dL of the groups treated with the doses 
of DIME 250 and 500 mg/kg, respectively. Serum insulin 
level was also significantly improved by treatment with 
DIME in the diabetic rats.
Effect on body weight
Body weight was slightly increased in the normal 
control rats (group I) compared to initial body weight 
whereas in the diabetic control rats (group II) there was 
a significant decrease in body weight. Glibenclamide 
(10 mg/kg) as well as the extracts (DIME 250 and 
500 mg/kg) treatment significantly (p < 0.05) prevented 
this reduction in body weight. Thus, based on weekly 
observation of the extract-treated diabetic rats, there were 
significant weight gains on day 21 compared to day 0 as 
shown in Table II.
Effect on lipid profile and serum transaminase
In diabetic rats, there was a significant increase in 
total cholesterol and triglycerides, as well as a significant 
decrease in HDL cholesterol in serum compared to that 
of normal controls. The standard drugs as well as DIME 
(250 and 500 mg/kg) plant extracts used in the experi-
mental study significantly decreased (p < 0.05) the levels 
of cholesterol and triglycerides whereas HDL cholesterol 
level was improved (Table III) after 21 days of treatment. 
Also, at the end of study, the serum transaminase, such as 
AST, ALT and ALP activity, was significantly elevated 
in the diabetic control groups. After supplementation 
with DIME (250 and 500 mg/kg) and glibenclamide 
(10 mg/kg), the serum transaminase level was restored to 
normal levels (Table III).
TABLE I - Effect of Dillenia indica leaves extract on blood glucose and insulin levels in diabetic rats
Groups/Treatments  Blood glucose level (mg/dL) Serum Insulin 
(IU/dL)Initial day Day 7 Day 14 Day 21
I: Vehicle 115.27 ± 4.5 113.34 ± 3.8 112.7 ± 5.2 113.82 ± 2.4 4.3 ± 0.25
II: STZ 258.41 ± 2.32 294.47 ± 5.47 348.7 ± 5.32 402 ± 3.47 1.2 ± 0.23
III: STZ+ DIME 
(250 mg/kg)
271.45 ± 5.17 265.4 ± 3.27* 178.3 ± 3.17* 139.43 ± 2.28* 2.3 ± 1.25*
IV: STZ+ DIME 
(500 mg/kg)
281.62 ± 3.4 215.27 ± 3.7* 155.24 ± 2.7** 124.32 ± 1.75** 2.9 ± 1.22/, *
V: Glibenclamide 
(10 mg/kg. b.w.)
274.27 ± 3.52 210.72 ± 4.25** 125.41 ± 3.45* 118.53 ± 3.5** 3.2 ± 1.23*
Data represent means ± S.E.M. of six animals in each group. *p<0.05, **p <0.001, when groups III and VI are compared with diabetic 
control, i.e. group II. SZT: streptozotocin (60 mg/kg body weight); DIME: D. indica
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DISCUSSION
Streptozotocin possess diabetogenic properties 
mediated by pancreatic beta cell destruction, the cells 
that normally regulate blood glucose levels by producing 
the hormone insulin, and this compound has been widely 
used to induce diabetes in experimental animals (Junod, 
1969). A 21-day treatment by DIME and glibenclamide 
in the STZ-induced diabetic rats significantly reduced the 
elevated blood sugar levels. This shows that the extract 
may not be able to produce the effect by one dose but by 
continuous treatment it acts effectively. It is well esta-
blished that glibenclamide (a long lasting sulfonylurea) 
acts mainly by stimulating insulin secretion. The DIME 
treatment also increased the insulin level. Thus, one pos-
sible antidiabetic mechanism of D. indica extract may be 
stimulation of insulin secretion.
STZ also induces oxidative stress or relative overlo-
ad of oxidants i.e. reactive oxygen species (Wright, 1999). 
D. indica leaves are rich in polyphenols and have an in 
vitro antioxidant effect (Arbianti, 2007). Various studies 
have shown that diabetes is associated with increased 
formation of free radicals and a decrease in antioxidant 
potential.
STZ-induced diabetes is characterized by severe 
loss in body weight and this reduction is due to loss or 
degeneration of structural proteins, as the structural pro-
teins are a known major contributor to body weight (Chen, 
Ianuzzo, 1982). A significant weight loss was observed in 
the diabetic group which was improved significantly by 
the DIME in treated groups.
The most commonly observed lipid abnormalities 
in diabetes are hypertriglyceridemia and hypercholestero-
lemia (Shepherd, 2005; Shirwaikar, 2006) and contribute 
to coronary artery disease (Arvind et al., 2005). In fact, 
lipid abnormalities accompanying with atherosclerosis 
is the major cause of cardiovascular disease in diabetes. 
Therefore, the ideal treatment of diabetes, in addition to 
glycemic control, should have a favorable effect on lipid 
profiles. Marked increases in total cholesterol, triglyce-
ride levels and decrease in HDL cholesterol have been 
observed in diabetic control rats. In the present study, the 
total cholesterol and triglycerides increased in the diabe-
tic control group and were reduced after the 21 days of 
treatment with DIME whereas the HDL cholesterol level 
was significantly increased. This suggests that the extract 
may inhibit the pathway of cholesterol synthesis (Rang, 
Dale, 1999).
TABLE II - Effect of DIME on body weight in diabetic rats
Groups Body weight (g) 
Initial day Day 7 Day 14 Day 21
I: Vehicle 215.2 ± 2.35 222.43 ± 4.22 225.41 ± 3.62 228.47 ± 3.17
II: STZ 225.23 ± 3.4 219.42 ± 3.85 211.35 ± 2.72 208.25 ± 4.32
III: STZ+ DIME (250 mg/kg) 228.27 ± 2.41 223.25 ± 3.4* 224.72 ± 2.37* 227.34 ± 3.42*
IV: STZ+ DIME (500 mg/kg) 225.52 ± 1.28 223.27 ± 3.21 225.72 ± 2.42* 227.33 ± 2.21*
V: Glibenclamide (10 mg/kg.b.w.) 225.34 ± 2.71 227.34 ± 2.36* 228.78 ± 2.35* 231.25 ± 1.83*
Data represent means ± S.E.M of six animals in each group. *p<0.05, when groups III and VI are compared with diabetic control 
(Group II). SZT: streptozotocin (60 mg/kg body weight); DIME: D. indica
TABLE III - Effect of DIME on lipid profile and serum enzymes in diabetic rats
Groups Total Cholesterol 
(mg/dL)
Triglycerides 
(mg/dL)
HDL cholesterol 
(mg/dL)
AST (U/L) ALT (U/L) ALP (U/L)
I 87.28 ± 3.8 82.42 ± 5.16 37.32 ± 2.9 56.27 ± 3.15 62.34 ± 3.27 123.34 ± 3.25
II 254.73 ± 7.6 150.52 ± 4.71 28.23 ± 2.2 145.34 ± 4.32 135.43 ± 3.13 240.37 ± 4.47 
III 125.32 ± 11.2* 117.24 ± 4.51* 34.24 ± 3.5* 94.32 ± 2.83** 88.45 ± 4.24* 179.52 ± 2.83* 
IV 110.47 ± 4.7* 92.24 ± 6.32* 41.35 ± 2.6* 73.25 ± 3.35* 76.54 ± 3.25** 153.44 ± 3.23* 
V 98.72 ± 5.3** 83.47 ± 4.5* 45.28 ± 4.8** 65.53 ± 4.25** 71.25 ± 2.45* 131.24 ± 2.43*
Data represent means ± S.E.M. of six animals in each group. *p<0.05, **p <0.001, when groups III and VI are compared with diabetic 
control (Group II). SZT: streptozotocin (60 mg/kg body weight); DIME: D. indica; HDL: high-density lipoprotein; AST: aspartate 
aminotransferase: ALT: alanine aminotransferase: Alp: alkaline phosphatase
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Elevated transaminase such as AST, ALT and ALP 
was observed in diabetic rats and indicates hepatic dama-
ge. The elevated transaminase activities were significantly 
reduced by the DIME treatment. Diabetic complications 
such as increased gluconeogenesis and ketogenesis may be 
due to elevated transaminase activity (Ghosh, Suryawansi, 
2001). These results suggest that DIME may also act as a 
hepatoprotective agent.
The present study demonstrated that DIME could 
be useful in the management of diabetes associated with 
abnormalities in lipid profiles and transaminase. The study 
needs to be validated in human volunteers prior to propo-
sed usage of DIME in other human volunteers.
CONCLUSION
Based on these results, it may be concluded that the 
antidiabetic activity of DIME may sensitize the insulin re-
ceptor or stimulate the secretion of insulin from beta cells 
of Islets of Langerhans in pancreas of STZ-induced diabetic 
rats, where this was supported by improved in vitro antio-
xidant status. The extract also improved other biochemical 
parameters associated with diabetes. Therefore, the present 
study clearly reveals the importance of leaves of D. indica as 
an economical antidiabetic agent. The plant bears potential 
for further research to isolate the antidiabetic principle.
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